Are there studies to support the effectiveness of FirstLine Therapy and Medical Foods?
In a recently completed 12-week, open-labeled, randomized, 2-arm study of 44 subjects fulfilling 3 or more metabolic syndrome criteria, individuals who participated in the UltraMeal® Plus 360° Medical Food Program were shown to have: • Statistically greater reductions in lipid parameters • Fasting serum cholesterol • Cholesterol/HDL ratio • Triglycerides • Triglyceride/HDL ratio • Statistically greater reduction in serum homocysteine • Significant increase in HDL (“good”) cholesterol • Persistent lowering effects on apoB and apoB/apoA1 ratio • ApoB may be a better indicator of CVD risk than total cholesterol or LDL • ApoB/apoA1 ratio is a newly recognized, increasingly significant indicator of CVD risk Studies conducted at the Functional Medicine Research Center (FMRC)—the clinical research arm of Metagenics—show positive effects of the UltraGlycemX® Medical Food on: • Fasting glucose • Fasting insulin • Postprandial glucose • Postprandial insulin • Triglycerides • Triglyceride/HDL rat
